BioSpace News Archive

Results published in first paper from 18-month analysis of ongoing pivotal Phase 3 trial were generally consistent with overall efficacy and safety data reported in previously published 12-month analysis.

Telemedicine Offers an Alternative to Healthcare Services for Non-Emergent Routine Illnesses

10-minute test for coronavirus exposure utilizing blood from a finger prick can be performed anywhere by trained professionals, e.g. airports, schools, work, doctor’s office

Quidel Corporation announced that Quidel has received Emergency Use Authorization from the U.S. Food and Drug Administration to market its Lyra® SARS-CoV-2 Assay, a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal or oropharyngeal swab specimens from patients suspected of COVID-19 by their healthcare provider.

Yokogawa Electric Corporation announces that it has developed the SU10 Single CellomeTM Unit, a device that uses a nanopipette*1 to inject substances such as genes and drugs and aspirate intracellular materials at target locations in individual cells.

Cigna Corporation announced the results as of 5:00 p.m., New York City time, on March 17, 2020 of its previously announced offers to purchase for cash up to $500,000,000 of Cigna Holding Company’s 4.000% Senior Notes due 2022

Arrowhead Pharmaceuticals Inc. announced that as an inducement to entering into employment with the Company, on March 11, 2020, the Compensation Committee of the Board of Directors approved “inducement” grants to 31 new employees under Rule 5635 of the NASDAQ Marketplace Rules.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that they have entered into a consent decree agreement with staff of the U.S. Federal Trade Commission (FTC) regarding AbbVie’s pending acquisition of Allergan.

CARB-X is awarding Microbiotix, a US-based clinical-stage biopharmaceutical company in Worcester, MA, up to US$2.86 million in non-dilutive funding to develop a new oral antibiotic to treat multidrug-resistant gonorrhea, a sexually transmitted disease caused by bacteria that have developed resistance to all but one existing antibiotic.

Starting Wednesday, BayCare patients who have been instructed by their doctor to be tested for COVID-19 will be able to provide a specimen for testing without leaving their cars.